BioNexus Gene Lab Corp. (BGLC) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth No data.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth No data.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth No data.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth No data.
13/47
1.4 / 5 stars
All 47 Win/Lose results and 73 gray no-data contests shown below
Every strict quarterly win earns 1 point. A loss or tie earns 0. A contest with no data is a gray cell, neither a win nor a loss, and leaves the total: stars are 5 × points won ÷ contests with data.
Trailing 1 year (4 quarters): 1 wins, 7 losses, 4 no dataLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/2 |
LoseBGLC / S&P -8.92% / 15.20% |
LoseBGLC / S&P -67.27% / 15.00% |
No dataBGLC / S&P / 50.40% |
| 2026-Q10/2 |
LoseBGLC / S&P -45.80% / -4.33% |
LoseBGLC / S&P -42.69% / 11.30% |
No dataBGLC / S&P / 27.70% |
| 2025-Q40/2 |
LoseBGLC / S&P -27.79% / 2.65% |
LoseBGLC / S&P -21.93% / 9.00% |
No dataBGLC / S&P / 13.40% |
| 2025-Q31/2 |
WinBGLC / S&P 78.18% / 8.12% |
LoseBGLC / S&P 2.22% / 4.61% |
No dataBGLC / S&P / 13.45% |
| 2025-Q21/2 |
WinBGLC / S&P 30.08% / 10.94% |
LoseBGLC / S&P 4.01% / 4.83% |
No dataBGLC / S&P / 10.63% |
| 2025-Q10/2 |
LoseBGLC / S&P -15.71% / -4.27% |
LoseBGLC / S&P -5.21% / 4.98% |
No dataBGLC / S&P / 10.57% |
| 2024-Q40/2 |
LoseBGLC / S&P -37.08% / 2.41% |
LoseBGLC / S&P -2.66% / 5.25% |
No dataBGLC / S&P / 6.15% |
| 2024-Q30/2 |
LoseBGLC / S&P -6.32% / 5.89% |
LoseBGLC / S&P -10.42% / 5.89% |
No dataBGLC / S&P / 6.11% |
| 2024-Q20/2 |
LoseBGLC / S&P -32.72% / 4.28% |
LoseBGLC / S&P -11.35% / 5.38% |
No dataBGLC / S&P / 5.12% |
| 2024-Q11/2 |
WinBGLC / S&P 33.21% / 10.56% |
LoseBGLC / S&P -4.88% / 5.71% |
No dataBGLC / S&P / 5.59% |
| 2023-Q40/2 |
LoseBGLC / S&P -39.08% / 11.69% |
LoseBGLC / S&P -10.60% / 6.81% |
No dataBGLC / S&P / 7.78% |
| 2023-Q30/2 |
LoseBGLC / S&P -67.19% / -3.27% |
LoseBGLC / S&P -8.80% / 7.52% |
No dataBGLC / S&P / -5.03% |
| 2023-Q20/2 |
LoseBGLC / S&P -59.07% / 8.74% |
LoseBGLC / S&P -16.02% / 9.50% |
No dataBGLC / S&P / -8.57% |
| 2023-Q10/2 |
LoseBGLC / S&P -43.16% / 7.50% |
LoseBGLC / S&P -20.59% / 10.77% |
No dataBGLC / S&P / -15.69% |
| 2022-Q40/2 |
LoseBGLC / S&P -10.38% / 7.56% |
LoseBGLC / S&P -18.21% / 11.88% |
No dataBGLC / S&P / -17.99% |
| 2022-Q30/2 |
LoseBGLC / S&P -7.02% / -4.88% |
LoseBGLC / S&P -20.42% / 13.47% |
No dataBGLC / S&P / -1.41% |
| 2022-Q20/2 |
LoseBGLC / S&P -33.33% / -16.10% |
LoseBGLC / S&P -10.34% / 13.71% |
No dataBGLC / S&P / 11.04% |
| 2022-Q10/2 |
LoseBGLC / S&P -19.72% / -4.60% |
LoseBGLC / S&P 9.96% / 15.97% |
No dataBGLC / S&P / 42.23% |
| 2021-Q42/2 |
WinBGLC / S&P 80.51% / 11.03% |
WinBGLC / S&P 17.31% / 15.00% |
No dataBGLC / S&P / 96.40% |
| 2021-Q32/2 |
WinBGLC / S&P 2.61% / 0.58% |
WinBGLC / S&P 94.64% / 10.77% |
No dataBGLC / S&P / 69.42% |
| 2021-Q21/2 |
LoseBGLC / S&P -45.24% / 8.55% |
WinBGLC / S&P 223.66% / 6.58% |
No dataBGLC / S&P / 51.81% |
| 2021-Q11/1 |
No dataBGLC / S&P / 6.17% |
WinBGLC / S&P 271.41% / -1.06% |
No dataBGLC / S&P / 7.39% |
| 2020-Q41/1 |
No dataBGLC / S&P / 12.15% |
WinBGLC / S&P 8872.03% / -3.72% |
No dataBGLC / S&P / -33.42% |
| 2020-Q31/1 |
No dataBGLC / S&P / 8.93% |
WinBGLC / S&P 8683.27% / -2.04% |
No dataBGLC / S&P / -27.10% |
| 2020-Q21/1 |
No dataBGLC / S&P / 20.54% |
WinBGLC / S&P 2719.46% / -0.46% |
No dataBGLC / S&P / -27.11% |
| 2020-Q11/1 |
No dataBGLC / S&P / -19.60% |
WinBGLC / S&P 1218.09% / 3.47% |
No dataBGLC / S&P / -14.75% |
| 2019-Q40/0 |
No dataBGLC / S&P / 9.07% |
No dataBGLC / S&P / 5.36% |
No dataBGLC / S&P / 2.99% |
| 2019-Q30/0 |
No dataBGLC / S&P / 1.70% |
No dataBGLC / S&P / 5.02% |
No dataBGLC / S&P / 0.21% |
| 2019-Q20/0 |
No dataBGLC / S&P / 4.30% |
No dataBGLC / S&P / 6.64% |
No dataBGLC / S&P / 8.65% |
| 2019-Q10/0 |
No dataBGLC / S&P / 13.65% |
No dataBGLC / S&P / 8.12% |
No dataBGLC / S&P / 14.29% |
| 2018-Q40/0 |
No dataBGLC / S&P / -13.52% |
No dataBGLC / S&P / 9.05% |
No dataBGLC / S&P / 18.23% |
| 2018-Q30/0 |
No dataBGLC / S&P / 7.71% |
No dataBGLC / S&P / 10.21% |
No dataBGLC / S&P / 19.06% |
| 2018-Q20/0 |
No dataBGLC / S&P / 3.43% |
No dataBGLC / S&P / 9.03% |
No dataBGLC / S&P / 14.46% |
| 2018-Q10/0 |
No dataBGLC / S&P / -0.76% |
No dataBGLC / S&P / 7.68% |
No dataBGLC / S&P / 12.46% |
| 2017-Q40/0 |
No dataBGLC / S&P / 6.64% |
No dataBGLC / S&P / 7.03% |
No dataBGLC / S&P / 13.82% |
| 2017-Q30/0 |
No dataBGLC / S&P / 4.48% |
No dataBGLC / S&P / 5.68% |
No dataBGLC / S&P / 17.57% |
| 2017-Q20/0 |
No dataBGLC / S&P / 3.09% |
No dataBGLC / S&P / 4.83% |
No dataBGLC / S&P / 17.74% |
| 2017-Q10/0 |
No dataBGLC / S&P / 6.07% |
No dataBGLC / S&P / 3.67% |
No dataBGLC / S&P / 13.32% |
| 2016-Q40/0 |
No dataBGLC / S&P / 3.82% |
No dataBGLC / S&P / 2.09% |
No dataBGLC / S&P / 7.05% |
| 2016-Q30/0 |
No dataBGLC / S&P / 3.85% |
No dataBGLC / S&P / 0.20% |
No dataBGLC / S&P / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | BGLC total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -73.59% | 20.78% |
| Annualized return | -73.59% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | BGLC total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -98.84% | 83.14% |
| Annualized return | -59.01% | 12.86% |
10Y · 2021-01-08 to 2026-08-27
| Metric | BGLC total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.43% | 319.30% |
| Annualized return | -40.37% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |